FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to pharmacology and clinical medicine, and describes a pharmaceutical composition in the form of tablets containing a S1P receptor modulator representing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and/or a pharmaceutically acceptable salt thereof, and additive substances: microcrystalline cellulose, sodium carboxymethyl starch, calcium stearate or magnesium stearate in the following proportions.
EFFECT: composition is more stable and has less side effects.
3 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATMENT OF DEMYELINATING DISEASES (VERSIONS) AND METHOD OF ITS OBTAINING | 2012 |
|
RU2482842C1 |
| PHARMACEUTICAL COMPOSITION EXHIBITING IMPROVED FLOWABILITY, DRUG PREPARATION, METHOD FOR PREPARING AND USING | 2012 |
|
RU2496486C1 |
| COMPOSITIONS CONTAINING MODULATORS OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR | 2008 |
|
RU2779056C2 |
| ORAL PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475237C2 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475236C2 |
| S1P RECEPTOR MODULATORS FOR MULTIPLE SCLEROSIS TREATMENT | 2007 |
|
RU2617502C2 |
| SIP RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS | 2007 |
|
RU2495664C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATING DEMYELINIATING DISEASES | 2013 |
|
RU2530626C1 |
| ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
